Showing results (151-160 of 6,005) with videos related to

Sort By:
Pageof 601
Molecular Cancer Therapeutics|September 25, 2019
Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 InhibitorsVindhya Udhane, Cristina Maranto, David T Hoang, et al.
Molecular Cancer Therapeutics|October 5, 2019
A Multifunctional Therapy Approach for Cancer: Targeting Raf1- Mediated Inhibition of Cell Motility, Growth, and Interaction with the MicroenvironmentLimin Zhang, Abhinandan Pattanayak, Wenqi Li, et al.
Molecular Cancer Therapeutics|October 5, 2019
Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the StromaCho-Hao Lin, Khadija H Elkholy, Nissar A Wani, et al.
Molecular Cancer Therapeutics|March 3, 2019
Preclinical Development of a WT1 Oral Cancer Vaccine Using a Bacterial Vector to Treat Castration-Resistant Prostate CancerKoichi Kitagawa, Reina Gonoi, Maho Tatsumi, et al.
Molecular Cancer Therapeutics|March 3, 2019
Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor AngiogenesisOlga Karginova, Claire M Weekley, Akila Raoul, et al.
Molecular Cancer Therapeutics|November 15, 2018
The T197A Knock-in Model of Cdkn1b Gene to Study the Effects of p27 Restoration In VivoCarmela De Marco, Nicola Rinaldo, Fernanda De Vita, et al.
Molecular Cancer Therapeutics|February 22, 2019
β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder CancerGeorgios Kallifatidis, Diandra K Smith, Daley S Morera, et al.
Molecular Cancer Therapeutics|February 22, 2019
TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical ModelsHiroki Irie, Kimihiro Ito, Yayoi Fujioka, et al.
Molecular Cancer Therapeutics|February 10, 2021
Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEKDavid K Lau, Ian Y Luk, Laura J Jenkins, et al.
Molecular Cancer Therapeutics|February 10, 2021
V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate CancerBradleigh Whitton, Haruko Okamoto, Matthew Rose-Zerilli, et al.
Pageof 601